Follicular Lymphoma in Chile in the Adult Public Cancer Program: The Impact of Chemoimmunotherapy
Our study shows a female predominance in patients with FL in Chile and confirms superior response and survival outcomes with adding rituximab to chemotherapy. Our study also confirms a poor OS in patients who experience POD24.
Authors
- Marvila Intriago
- Cecilia Hales
- Jorge J. Castillo (ORCID: https://orcid.org/0000-0001-9490-7532)
- Jacqueline Oliva (ORCID: https://orcid.org/0000-0001-9334-2066)
- Susana Calderon (ORCID: https://orcid.org/0000-0002-5823-8877)
- Valeska Vega
- Camila Peña (ORCID: https://orcid.org/0000-0002-8076-2077)
- Álvaro Pizarro
- María Elena Cabrera (ORCID: https://orcid.org/0000-0001-9059-3871)
- M. Luisa Gonzalez (ORCID: https://orcid.org/0000-0003-1769-9041)
- Hernán Rojas
- Marisa Capurro
- Christine Rojas
- Bernardita Rojas (ORCID: https://orcid.org/0009-0002-1986-2711)
Institutions
- Harvard University (US)
- Hospital del Salvador (CL)
- Hospital Carlos Van Buren (CL)
- Dana-Farber Cancer Institute (US)
- Hospital San Juan de Dios (CL)
- Hospital la Serena (CL)
- Complejo Asistencial Sótero del Río (CL)
- Hospital Dr. Gustavo Fricke (CL)
- Hospital Regional de Arica Doctor Juan Noé Crevani (CL)
- Hospital San Borja Arriarán (CL)
- Hospital Doctor Hernán Henríquez Aravena (CL)
- Hospital Base (CL)
- Hospital Las Higueras (CL)
- University of Chile (CL)
Publication Details
- Journal
- Cancer Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cnr2.2126
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00